Systemic therapies for salivary gland carcinomas: an overview of published clinical trials

Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
MEDICINA ORAL S L
Autores
SILVA, Luan Cesar
PEREZ-DE-OLIVEIRA, Maria Eduarda
PEDROSO, Caique Mariano
LEITE, Amanda Almeida
SANTOS-SILVA, Alan Roger
LOPES, Marcio Ajudarte
MARTINS, Manoela Domingues
WAGNER, Vivian Petersen
KOWALSKI, Luiz Paulo
Citação
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, v.29, n.2, p.e280-e287, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: There is no consensus about effective systemic therapy for salivary gland carcinomas (sgcs). Our aim was summarized the clinical trials assessing the systemic therapies (ST) on sgcs. Material and Methods: Electronic searches were carried out through MEDLINE/pubmed, EMBASE, Scopus, Web of Science, and the Cochrane Library databases, and gray literature. Results: Seventeen different drugs were evaluated, and the most frequent histological subtype was adenoid cystic carcinoma (n=195, 45.5%). Stable disease, observed in 11 ST, achieved the highest rate in adenoid cystic carcinoma treated with sunitinib. The highest complete (11.1%) and partial response (30.5%) rates were seen in androgen receptor -positive tumors treated with leuprorelin acetate. Conclusions: Despite all the advances in this field, there is yet no effective evidence -based regimen of ST, with all the clinical trials identified showing low rates of complete and partial responses. Further, translational studies are urgently required to characterize molecular targets and effective ST.
Palavras-chave
Clinical trials, salivary gland cancer, systemic therapies
URI
https://observatorio.fm.usp.br/handle/OPI/59120
Referências
  1. Airoldi M, 2001, CANCER, V91, P541, DOI 10.1002/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y
  2. Airoldi M, 2017, AM J CLIN ONCOL-CANC, V40, P86, DOI 10.1097/COC.0000000000000112
  3. Alfieri S, 2017, ORAL ONCOL, V66, P58, DOI 10.1016/j.oraloncology.2016.12.016
  4. Argiris A, 2011, CANCER-AM CANCER SOC, V117, P3374, DOI 10.1002/cncr.25852
  5. Chau NG, 2012, ANN ONCOL, V23, P1562, DOI 10.1093/annonc/mdr522
  6. Coca-Pelaz A, 2015, EUR ARCH OTO-RHINO-L, V272, P799, DOI 10.1007/s00405-014-3053-z
  7. Colevas AD, 2018, J NATL COMPR CANC NE, V16, P479, DOI 10.6004/jnccn.2018.0026
  8. Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448
  9. Fushimi C, 2018, ANN ONCOL, V29, P979, DOI 10.1093/annonc/mdx771
  10. Geiger JL, 2021, J CLIN ONCOL, V39, P1909, DOI 10.1200/JCO.21.00449
  11. Gilbert J, 2006, HEAD NECK-J SCI SPEC, V28, P197, DOI 10.1002/hed.20327
  12. Goncalves PH, 2017, ONCOTARGET, V8, P32918, DOI 10.18632/oncotarget.16464
  13. Guimaraes DM, 2016, ONCOTARGET, V7, P42447, DOI 10.18632/oncotarget.9884
  14. Haddad R, 2003, ORAL ONCOL, V39, P724, DOI 10.1016/S1368-8375(03)00097-6
  15. Hanna GJ, 2020, CANCER-AM CANCER SOC, V126, P3972, DOI 10.1002/cncr.33036
  16. Hong MH, 2018, HEAD NECK-J SCI SPEC, V40, P55, DOI 10.1002/hed.24933
  17. Hotte SJ, 2005, J CLIN ONCOL, V23, P585, DOI 10.1200/JCO.2005.06.125
  18. Imamura Y, 2022, JPN J CLIN ONCOL, V52, P293, DOI 10.1093/jjco/hyac008
  19. JONES AS, 1993, BRIT J CANCER, V67, P112, DOI 10.1038/bjc.1993.19
  20. Kim Y, 2017, CANCER-AM CANCER SOC, V123, P1958, DOI 10.1002/cncr.30537
  21. Le XN, 2022, ONCOLOGIST, DOI 10.1093/oncolo/oyac080
  22. LICITRA L, 1991, CANCER, V68, P1874, DOI 10.1002/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S
  23. Locati LD, 2009, ORAL ONCOL, V45, P574, DOI 10.1016/j.oraloncology.2008.07.010
  24. Locati LD, 2021, J CLIN ONCOL, V39, P4061, DOI 10.1200/JCO.21.00468
  25. Lopes MA, 2006, OTOLARYNG HEAD NECK, V134, P622, DOI 10.1016/j.otohns.2005.12.012
  26. Louredo BVR, 2021, J ORAL PATHOL MED, V50, P435, DOI 10.1111/jop.13151
  27. Mueller SK, 2022, J CLIN MED, V11, DOI 10.3390/jcm11030720
  28. Noguchi K, 2022, MOL CLIN ONCOL, V16, DOI 10.3892/mco.2022.2508
  29. Pfeffer MR, 2007, ORAL ONCOL, V43, P33, DOI 10.1016/j.oraloncology.2005.12.026
  30. Rodriguez CP, 2020, CLIN CANCER RES, V26, P837, DOI 10.1158/1078-0432.CCR-19-2214
  31. Sahara S, 2021, AM J CANCER RES, V11, P4092
  32. Silva LC, 2022, J ORAL PATHOL MED, V51, P553, DOI 10.1111/jop.13252
  33. Wagner V.P., 2018, Scientific Reports, V8, P1
  34. Wagner VP, 2016, ONCOTARGET, V7, P73032, DOI 10.18632/oncotarget.12195
  35. Zang SM, 2022, QUANT IMAG MED SURG, V12, P2841, DOI 10.21037/qims-21-836

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP